Trial Profile
Phase 2 Study to Evaluate the Efficacy of High Dose Ranibizumab as Adjuvant in the Treatment of Choroidal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Choroid neoplasms; Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms Cohort 2
- 08 Aug 2011 Planned end date changed from Aug 2011 to Aug 2012 as reported by ClinicalTrials.gov.
- 08 Dec 2010 New trial record